Panic Disorder Pipeline Analysis Report 2025
Description
Panic disorder, a type of anxiety disorder, is characterized by recurrent, unexpected panic attacks and a persistent fear of future attacks. The prevalence of anxiety disorders is projected to reach 4565.65 per 100,000 people by 2030. Current first-line treatments include selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. However, there remains a significant unmet clinical need for more effective therapies, as these options often come with side effects and limited long-term efficacy. The growing focus on developing innovative treatments, including novel drug classes and personalized medicine, is expected to drive pipeline growth in the coming years.
Report Coverage
The Panic Disorder Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into panic disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for panic disorder. The panic disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The panic disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with panic disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to panic disorder.
Panic Disorder Pipeline Outlook
Panic disorder is an anxiety disorder marked by recurrent, unexpected panic attacks which is an intense episode of fear that peaks within minutes. These attacks often lead to persistent worry about future attacks and significant behavioral changes. Panic disorder can occur due to genetic factors, stress, or brain chemistry imbalances.
Panic disorder is primarily treated with selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and cognitive behavioral therapy. SSRIs help regulate mood, while benzodiazepines provide rapid relief. However, long-term solutions are being explored through new drug classes and targeted therapies.
Panic Disorder Epidemiology
The global prevalence of anxiety disorders, including panic disorder, is projected to rise significantly, reaching 4565.65 per 100,000 people by 2030 and 5752.68 by 2050. In the United States, around 19.1% of adults experience anxiety disorders annually, including panic disorder. In India, the increase in anxiety disorder prevalence ranges from 23.7% to 35%. These trends underscore a growing need for advanced treatments.
Panic Disorder Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of panic disorder drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total panic disorder clinical trials.
Panic Disorder – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the panic disorder pipeline analysis include small molecules, biologics, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for panic disorder.
Panic Disorder Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR panic disorder drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in panic disorder clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for panic disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of panic disorder drug candidates.
Drug: Hydroxyzine
The study, sponsored by Sultan Qaboos University, aims to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. This Phase 4 study will assess the feasibility, effectiveness, and side effects of hydroxyzine. Expected to conclude by December 2026, the study will enroll around 80 participants to provide valuable insights for future research.
Drug: HB-1
The Phase 2 clinical trial sponsored by Honeybrains Biotech LLC aims to evaluate the safety and efficacy of HB-1 for treating panic disorder. This multicenter, randomized, double-blind, placebo-controlled study will involve approximately 240 participants, aged 18 to 65, with panic disorder. The study is expected to be completed by February 2026, with primary results anticipated in January 2026.
Drug: Darigabat
Cerevel Therapeutics, LLC is sponsoring a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of darigabat (25 mg twice daily) in participants with panic disorder, compared to a placebo. The study, enrolling approximately 246 participants, started in July 2023 and is expected to be completed by April 2025, with primary results anticipated by March 2025.
Reasons To Buy This Report
The Panic Disorder Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for panic disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into panic disorder collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Panic Disorder – Pipeline Insight Report
Panic Disorder Market
Anxiety and Depression Treatment Market
Generalized Anxiety Disorder Market
Global Clinical Trials Market
Report Coverage
The Panic Disorder Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into panic disorder therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for panic disorder. The panic disorder report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The panic disorder pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with panic disorder treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to panic disorder.
Panic Disorder Pipeline Outlook
Panic disorder is an anxiety disorder marked by recurrent, unexpected panic attacks which is an intense episode of fear that peaks within minutes. These attacks often lead to persistent worry about future attacks and significant behavioral changes. Panic disorder can occur due to genetic factors, stress, or brain chemistry imbalances.
Panic disorder is primarily treated with selective serotonin reuptake inhibitors (SSRIs), benzodiazepines, and cognitive behavioral therapy. SSRIs help regulate mood, while benzodiazepines provide rapid relief. However, long-term solutions are being explored through new drug classes and targeted therapies.
Panic Disorder Epidemiology
The global prevalence of anxiety disorders, including panic disorder, is projected to rise significantly, reaching 4565.65 per 100,000 people by 2030 and 5752.68 by 2050. In the United States, around 19.1% of adults experience anxiety disorders annually, including panic disorder. In India, the increase in anxiety disorder prevalence ranges from 23.7% to 35%. These trends underscore a growing need for advanced treatments.
Panic Disorder Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of panic disorder drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Biologics
- Gene Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total panic disorder clinical trials.
Panic Disorder – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the panic disorder pipeline analysis include small molecules, biologics, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for panic disorder.
Panic Disorder Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR panic disorder drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in panic disorder clinical trials:
- Honeybrains Biotech LLC
- Cerevel Therapeutics, LLC
- Tilray
- Addex Pharmaceuticals
- Neurelis
- VistaGen Therapeutics
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for panic disorder. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of panic disorder drug candidates.
Drug: Hydroxyzine
The study, sponsored by Sultan Qaboos University, aims to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. This Phase 4 study will assess the feasibility, effectiveness, and side effects of hydroxyzine. Expected to conclude by December 2026, the study will enroll around 80 participants to provide valuable insights for future research.
Drug: HB-1
The Phase 2 clinical trial sponsored by Honeybrains Biotech LLC aims to evaluate the safety and efficacy of HB-1 for treating panic disorder. This multicenter, randomized, double-blind, placebo-controlled study will involve approximately 240 participants, aged 18 to 65, with panic disorder. The study is expected to be completed by February 2026, with primary results anticipated in January 2026.
Drug: Darigabat
Cerevel Therapeutics, LLC is sponsoring a Phase 2 clinical trial to assess the efficacy, safety, and tolerability of darigabat (25 mg twice daily) in participants with panic disorder, compared to a placebo. The study, enrolling approximately 246 participants, started in July 2023 and is expected to be completed by April 2025, with primary results anticipated by March 2025.
Reasons To Buy This Report
The Panic Disorder Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for panic disorder. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into panic disorder collaborations, regulatory environments, and potential growth opportunities.
Key Questions Answered in the Panic Disorder – Pipeline Insight Report
- What is the current landscape of panic disorder pipeline drugs?
- Which companies/institutions are developing panic disorder emerging drugs?
- How many phase II drugs are currently present in panic disorder pipeline drugs?
- Which company is leading the panic disorder pipeline development activities?
- What is the current panic disorder therapeutic assessment?
- What are the opportunities and challenges present in the panic disorder drug pipeline landscape?
- What is the efficacy and safety profile of panic disorder pipeline drugs?
- Which companies/institutions are involved in panic disorder collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in panic disorder?
Panic Disorder Market
Anxiety and Depression Treatment Market
Generalized Anxiety Disorder Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Panic Disorder
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Panic Disorder
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Panic Disorder: Epidemiology Snapshot
- 5.1 Panic Disorder Incidence by Key Markets
- 5.2 Panic Disorder – Patients Seeking Treatment in Key Markets
- 6 Panic Disorder: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Panic Disorder: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Panic Disorder, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Panic Disorder Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Panic Disorder Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Hydroxyzine
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Panic Disorder Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: HB-1
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Darigabat
- 11.2.3 Other Drugs
- 12 Panic Disorder Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug 1
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Panic Disorder Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Panic Disorder, Key Drug Pipeline Companies
- 14.1 Honeybrains Biotech LLC
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Cerevel Therapeutics, LLC
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Tilray
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Addex Pharmaceuticals
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Neurelis
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 VistaGen Therapeutics
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
